Ascentage Pharma Group International
AAPGV
Other OTC17.38
USD
+0.13
- -
Ascentage Pharma Group International
AAPGV
(Other OTC)
Recent
price
17.38
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) is a global, commercial-stage, integrated biopharmaceutical company that discovers, develops, and commercializes novel, differentiated therapies targeting apoptosis pathways to address unmet medical needs primarily in hematological malignancies, chronic hepatitis B, and age-related diseases. The company offers olverembatinib (HQP1351), a third-generation BCR-ABL1 inhibitor approved in China for drug-resistant chronic myeloid leukemia (CML) and under evaluation in multiple Phase 3 trials including POLARIS-2 for CML, POLARIS-1 for frontline Ph+ acute lymphocytic leukemia (ALL), and POLARIS-3 for SDH-deficient gastrointestinal stromal tumors (GIST); lisaftoclax (APG-2575), a Bcl-2 selective inhibitor approved in China in July 2025 for relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) following BTK inhibitor therapy and advancing in Phase 3 trials such as GLORA for CLL/SLL, GLORA-3 for acute myeloid leukemia (AML), and GLORA-4 for myelodysplastic syndrome (MDS); APG-115, an oral MDM2-p53 inhibitor for solid tumors and hematological malignancies; APG-1252, a dual Bcl-2/Bcl-xL inhibitor for small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumors, and non-Hodgkin's lymphoma; APG-1387, an IAP inhibitor for advanced solid tumors and chronic hepatitis B; APG-2449, an oral inhibitor of FAK, ROS1, and ALK kinases; and APG-5918, a selective EED inhibitor. Founded in 2009 and headquartered at 68 Xinqing Road, Suzhou Industrial Park, Suzhou, China, with additional operations in Rockville, Maryland, USA, the company conducts over 40 clinical trials across the United States, Australia, Europe, and China, targeting oncology indications like AML, ALL, CLL, MDS, multiple myeloma, and solid tumors, while maintaining global collaborations with entities including Takeda, Innovent Biologics, AstraZeneca, Merck, Pfizer, Dana-Farber Cancer Institute, Mayo Clinic, and MD Anderson Cancer Center. Recent developments include the closing of a US$75 million equity investment from Takeda in June 2024, granting Takeda an exclusive option for global rights (ex-China) to olverembatinib; NMPA approval and commercial launch of lisaftoclax in China in July 2025; 93% year-over-year growth in olverembatinib product sales to US$30.3 million in the first half of 2025 driven by National Reimbursement Drug List (NRDL) expansion; FDA clearance for a Phase 1 trial in August 2025; and announcements of positive clinical data presentations at the 2025 American Society of Hematology (ASH) Annual Meeting in November-December 2025.